Stock listing
Clover Biopharmaceuticals Ltd.
Selected listing: 2197 · HKEX · HKD · HK
Clover Biopharmaceuticals Ltd. (HKEX:2197), Health Technology. Latest release Sep 30, 2026: 2026 Interim Report.
- Ticker
- HKEX:2197
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- HKEX
- Currency
- HKD
About Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a public company listed on the Hong Kong Stock Exchange under the ticker 2197. Clover focuses on developing innovative biopharmaceutical products to address unmet medical needs.
Latest news from Clover Biopharmaceuticals Ltd.
2026 Interim Report
September 30, 2026
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
September 6, 2026
Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
March 24, 2026
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
January 11, 2026
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
October 19, 2025
Research Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. company profile
View the public company page for Clover Biopharmaceuticals Ltd. on 6ix.
Clover Biopharmaceuticals Ltd. news
Read company news and market updates connected to Clover Biopharmaceuticals Ltd..
Clover Biopharmaceuticals Ltd. investor events
Find investor webinars, events, and replay context for Clover Biopharmaceuticals Ltd..